

Freedom of Information Request: Our Reference CTMUHB_356_23

You asked:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn's Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis in three months from the start of May 2023 to the end of July 2023 (or the latest available 3 months).

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

If data is unavailable for question 1 it would be helpful if you can provide the information at a department level (question 2).

Appendix A

Q1 – How many patients were treated with the following drugs for the following diseases in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)						
Adalimumab (Biosimilars)						
Apremilast						
Bimekizumab						
Brodalumab						
Certolizumab Pegol						
Deucravacitinib						
Etanercept (Enbrel)						
Etanercept (Biosimilars)						
Guselkumab						
Infliximab (Remicade)						
Infliximab (Biosimilars)						
Ixekizumab						
Risankizumab						
Secukinumab						
Tildrakizumab						

Ustekinumab						
Upadacitinib						
Vedolizumab						
Filgotinib						
Golimumab						
Mirikizumab						
Ozanimod						
Tofacitinib						
Abatacept						
Baricitinib						
Rituximab						
Sarilumab						
Tocilizumab						

We can confirm that the Health Board does not centrally record this information. The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Q2 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of May 2023 and the end of July 2023?

Please use the latest available 3 months if May to July is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)			
Adalimumab (Biosimilars)			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept (Enbrel)			
Etanercept (Biosimilars)			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			

Ozanimod			
Tofacitinib			
Abatacept			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Please find below in relation to question 2, a table populated with the data that Medicines Management are able to provide. The period relates to the last 3 months available which is 1st May 2023 to 31st July 2023.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	5	6	82
Adalimumab (Biosimilars)	48	161	361
Apremilast	61		**
Bimekizumab	15		
Brodalumab	5		
Certolizumab Pegol	7	**	57
Deucravacitinib			
Etanercept (Enbrel)			28
Etanercept (Biosimilars)			298
Guselkumab	31		**
Infliximab (Remicade)		**	**
Infliximab (Biosimilars)	**	222	22
Ixekizumab	19		11
Risankizumab	52		
Secukinumab	5		81
Tildrakizumab	15		
Ustekinumab	35	145	15
Upadacitinib	12	8	12
Vedolizumab		80	

Filgotinib		**	**
Golimumab		**	57
Mirikizumab			
Ozanimod		**	
Tofacitinib		5	11
Abatacept			53
Baricitinib	5		25
Rituximab	**		39
Sarilumab			5
Tocilizumab			81